Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212466 · ClinicalTrials.gov registry record
MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 136
- Enrollment target
NCT06212466 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 136 participants.
The verdict
NCT06212466 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 136 participants
- Enrollment target
Study Summary
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Interventions
- DEVICE CardioFlux
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2025-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06212466
The ClinicalTrials.gov registry entry for NCT06212466 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genetesis, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux is the first listed.
NCT06212466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06212466 about?
NCT06212466 is a clinical study titled "MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)". A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic...
What is the current status of trial NCT06212466?
This trial is currently completed. The enrollment target is 136 participants. The study started on 2024-06-03. Estimated completion is 2025-04-15.
What interventions are being tested in trial NCT06212466?
The interventions under investigation include: CardioFlux (DEVICE).
Who is sponsoring clinical trial NCT06212466?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.